Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Achim Rittmeyer (Immenhausen, Germany), Achim Rittmeyer, Birgit Zwerger, Reinhardt Christian, Josef Rüschoff, Hans-Ulrich Schildhaus, Stefan Andreas. Checkpointinhibition in lung cancer – How to distinguish pseudoprogression from progressive disease. Eur Respir J 2016; 48: Suppl. 60, 4844

Member's Comments

No comment yet.

Related content which might interest you: Surgical treatment outcomes on early-stages of non-small-cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Lung cancer, has it changed in the last ten years? Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 ALK/EML4 translocation in non-squamous NSCLC and their predictors Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 PET-CT predictors of mediastinal dissemination in lung cancer Source: International Congress 2014 – Outcome prediction and imaging in thoracic surgery Year: 2014 Diagnosing lung cancer: Choosing the best for your patient Source: International Congress 2015 – Developments in lung cancer diagnosis Year: 2015 Does IASLC/ATS/ERS classification of lung adenocarcinoma impacts prognosis? Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Futile thoracotomy in lung cancer Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Lung cancer in women: What are particularities? Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Clinical and therapeutic characteristics of patients died due to radiation-induced pneumonitis Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Segmentectomy for second lung cancer after lobectomy Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013 Electrospray-mediated local chemotherapy of lung carcinoma in mice Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Improving survival for NSCLC patients in the national lung cancer audit Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Algorithm of preoperative N-staging of non-small cell lung cancer Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013 EBUS-TBNA for nodal restaging and relapse in lung cancer Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014 Predictors of lung cancer patients delay time in Serbia - a cross-sectional study Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Lung cancer after lymphoma: Disease characteristics, detection methods and clinical outcome Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases Year: 2013 Prognostic factors for survival in lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Completion pneumonectomy for lung cancer relapse after surgery- What is a real benefit? Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013